Table 3A.

Patient demographics and tumor characteristics.

IDSexAgeRaceSTS subtypeGradePrior therapyPostoperative therapyClinical outcome
1M31CaucasianFibrosarcoma2Neo-adjuvant IRTNoneN/A
2M65CaucasianPleomorphic liposarcoma3Prior disease, surgeryPembrolizumab + doxorubicinPD
Neo-adjuvant IRTIRTSD
3F51CaucasianMalignant PNSTN/ANeo-adjuvant IRTNoneN/A
4M28CaucasianExtraskeletal myxoid chondrosarcomaN/ANeo-adjuvant IRTNoneN/A
5F51Not reportedMyxoid liposarcoma1NoneNoneN/A
6M76CaucasianPleomorphic rhabdomyosarcomaN/ANoneNoneN/A
7M46African AmericanMyxoid liposarcoma3Neo-adjuvant doxorubicin + olaratumabNot reportedN/A
8M29African AmericanMyxoid liposarcoma1NoneIRTNot reported
9F49CaucasianMyxoid liposarcoma1NoneNot reportedN/A
10F54CaucasianUPS3Prior disease, treated with IRT, surgery, adj. epirubicin + ifosfamide (PD)Gemcitabine ± pazopanibPD
TrabectedinSD
11M93CaucasianMyxoid sarcoma2Prior disease, treated with surgery and adjuvant IRTNoneN/A
12M69CaucasianUPS3Neo-adjuvant IRTNot reportedN/A
13M44Not reportedUPS3NoneNot reportedN/A